APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X, Zhang, M-Q-Z, Conserva, F, Hosny, G, Selivanova, G, Bykov, V J N, Arnér, E S J, Wiman, K G·2013·Cell Death & Disease

DOI 10.1038/cddis.2013.417

Cited by (170)

Items 101–170 of 170

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy
Alex Aleshin, Peter L. Greenberg · 2018 · Blood Advances
p53 biology and reactivation for improved therapy in MDS and AML
Joanna Zawacka‐Pankau · 2024 · Biomarker Research
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
Vid Mlakar, Simona Jurković Mlakar, Laurence Lesne, Denis Marino, Komal S. Rathi, John M. Maris, Marc Ansari, Fabienne Gumy‐Pause · 2019 · Journal of Experimental & Clinical Cancer Research
Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
Elena Butturini, Giovanna Butera, Raffaella Pacchiana, Alessandra Carcereri de Prati, Sofia Mariotto, Massimo Donadelli · 2021 · Cells
PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation
Haruna FURUKAWA, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori et al. · 2017 · Cancer Science
PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK
Tao Lu, Yanmei Zou, Guogang Xu, Jane A. Potter, Garry L. Taylor, Qiuhong Duan, Qin Yang, Huihua Xiong, Hong Qiu, Dawei Ye et al. · 2016 · Oncotarget
Role of Thiol Reactivity for Targeting Mutant p53
Qiang Zhang, Jan Bergman, Klas G. Wiman, Vladimir J.N. Bykov · 2018 · Cell chemical biology
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Thomas Cluzeau, Michael L. Loschi, Pierre Fenaux, Rami S. Komrokji, David Andrew Sallman · 2021 · International Journal of Molecular Sciences
TAp73 promotes anti-senescence-anabolism not proliferation
Massimiliano Agostini, Maria Victoria Niklison-Chirou, Maria Valeria Catani, Richard A. Knight, Gerry Melino, Alessandro Rufini · 2014 · Aging
PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation
Yin, Zhi-Xian, Hang, Wei, Liu, Gang, Wang, Yi-Shu, Shen, Xiang-Feng, Sun, Qian-Hui, Li, Dong-Dong, Jian, Yong-Ping, Zhang, Yang-He, Quan, Cheng-Shi et al. · 2018 · Oncotarget
Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
Carlos C. Smith-Díaz, Nicholas J. Magon, Judith L. McKenzie, Mark B. Hampton, Margreet C.M. Vissers, Andrew B. Das · 2021 · Frontiers in Oncology
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
Ceder, Sophia, Eriksson, Sofi E., Liang, Ying Yu, Cheteh, Emarndeena H., Zhang, Si Min, Fujihara, Kenji M., Bianchi, Julie, Bykov, Vladimir J. N., Abrahmsen, Lars, Clemons, Nicholas J. et al. · 2021 · Cell Death & Disease
Current insights and future directions of Li-Fraumeni syndrome
Mohammad‐Salar Hosseini · 2024 · Discover Oncology
Activation of TAp73 and Inhibition of TrxR by Verteporfin for Improved Cancer Therapy in TP53 Mutant Pancreatic Tumors
Pilar Acedo, Aristi Potamitou Fernandes, Joanna Zawacka‐Pankau · 2019 · Future Science OA
Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy
Oleg N. Timofeev, Thorsten Stiewe · 2021 · Cancers
Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer
Mengqi Liu, Wensheng Liu, Yi Qin, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo, Shunrong Ji · 2020 · Experimental Hematology and Oncology
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells
Javier de la Rosa, Alejandro Urdiciain, María Victoria Zelaya, Idoya Zazpe, Bárbara Meléndez, JUAN ANTONIO REY, Miguel Angel Idoate, Javier S. Castresana · 2021 · International Journal of Oncology
APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Xuqin Xie, Chuanwen Fan, Bin Luo, Jing Zhang, Lasse D. Jensen, Jonas Burman, Carolin Jönsson, Anna Ljusberg, Peter Larsson, Zengren Zhao et al. · 2023 · Molecular Cancer Therapeutics
PTC596-Induced BMI-1 Inhibition Fights Neuroblastoma Multidrug Resistance by Inducing Ferroptosis
Giulia Elda Valenti, Antonella Roveri, Rina Venerando, Paola Menichini, Paola Monti, Bruno Tasso, Nicola Traverso, Cinzia Domenicotti, Barbara Marengo · 2023 · Antioxidants
Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
Michael Müller, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David Jones, Jochen Baßler, Sina Kreth, Sabine A. Stainczyk et al. · 2021 · Cancers
How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
Michael L. Loschi, Pierre Fenaux, Thomas Cluzeau · 2022 · Cancers
Covalent Fragments Acting as Tyrosine Mimics for Mutant p53-Y220C Rescue by Nucleophilic Aromatic Substitution
Theresa Klett, Jason Stahlecker, Simon Jaag, Benedikt Masberg, Cornelius Knappe, Michael Lämmerhofer, M.P. Coles, Thilo Stehle, Frank M. Boeckler · 2024 · ACS Pharmacology & Translational Science
Anticancer therapeutic strategies for targeting mutant p53-Y220C
Vitaly V. Chasov, Damir Davletshin, Elvina Gilyazova, Regina Mirgayazova, Anna A. Kudriaeva, Raniya Khadiullina, Youyong Yuan, Emil Bulatov · 2023 · Journal of Biomedical Research
Pharmacological Inhibition of TXNRD1 by a Small Molecule Flavonoid Butein Overcomes Cisplatin Resistance in Lung Cancer Cells
Rui Ryan Yang, Shibo Sun, Qiuyu Zhang, Haowen Liu, Ling Wang, Yao Meng, Na Chen, Zihan Wang, Haiyan Liu, Fengyun Ji et al. · 2024 · Biological Trace Element Research
Molecular features of giant-cell carcinoma of the lung: a case report and literature review
Xin Li, Zihe Zhang, Jinghao Liu, Dan Wang, Sen Wei, Jun Chen · 2018 · OncoTargets and Therapy
Restoration of conformation of mutant p53
J.A. Green, M. Von Euler, Lars Abrahmsén · 2018 · Annals of Oncology
Guiding bar motif of thioredoxin reductase 1 modulates enzymatic activity and inhibitor binding by communicating with the co-factor FAD and regulating the flexible C-terminal redox motif
Wuyang Shi, Shibo Sun, Haowen Liu, Yao Meng, Kangshuai Ren, Guoying Wang, Minghui Liu, Jiaqi Wu, Yue Zhang, Huang Huang et al. · 2024 · Redox Biology
Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia
Frank N. van Leeuwen · 2020 · Haematologica
Thioredoxin Reductase 1 as an Anticancer Drug Target
Edward E. Schmidt, Elias S.J. Arnér · 2016 · Springer eBooks
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Ramy Rahmé, Thorsten Braun, James J. Manfredi, Pierre Fenaux · 2023 · Biomedicines
Prima-1 and APR-246 in Cancer Therapy
Pavlína Zatloukalová, Michaela Galoczová, Bořivoj Vojtěšek · 2018 · Klinicka onkologie
Ferroptosis: Potential therapeutic targets and prognostic predictions for acute myeloid leukemia (Review)
Wenlu Zhang, Wen Wen, Ran Tan, Mei-Rui Zhang, Tan-Tan Zhong, Jianhong Wang, Haiping Chen, Xiaosheng Fang · 2024 · Oncology Letters
Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis
Ying‐Chu Lin, Chia‐Chen Ku, Kenly Wuputra, Deng‐Chyang Wu, Kazunari K. Yokoyama · 2024 · Cells
Discovery of novel organoarsenicals as robust thioredoxin reductase inhibitors for oxidative stress mediated cancer therapy
Wenyan She, Xuemin Shi, Tingting Liu, Yi Liu, Yi Liu · 2023 · Biochemical Pharmacology
Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants
Adam J. Nagourney, Joshua B. Gipoor, Steven Scott Evans, Paulo D’Amora, Max Duesberg, Paula J. Bernard, Federico R. Francisco, Robert Alan Nagourney · 2023 · Genes
Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma
Jingwei Yao, Mengqi Li, Yuelong Jiang, Nanye Yao, Yating Liu, Liemei Lv, Yuchen Li, Jiewen Huang, Jie Zha, Bing Xu · 2025 · Cell Death Discovery
Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions
Abhishek Maiti, Naval Guastad Daver · 2022 · Journal of Clinical Oncology
Ferroptosis in hematological malignancies: molecular mechanisms and therapeutic potential
Jiaxi Liu, Rui Liu, Jiyu Miao, Aili He · 2025 · Cellular Oncology
Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
Julia V. Milne, Bonnie Z. Zhang, Kenji Mark Fujihara, Swati Dawar, Wayne Allen Phillips, Nicholas James Clemons · 2021 · Scientific Reports
APR-246 increases tumor antigenicity independent of p53
Judith Michels, Divya Venkatesh, Cailian Liu, Sadna Budhu, Hong Zhong, Mariam Mathew George, Daniel Thach, Zhong‐Ke Yao, Ouathek Ouerfelli, Hengrui Liu et al. · 2023 · Life Science Alliance
Ferroptosis in gut pathophysiology: Molecular mechanisms and microbial regulation of iron metabolism and oxidative stress
Wentao Li, Qi Jing, Qinjie Liu, Yi Yang, Jie Wu · 2026 · Advances in Redox Research
Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
Iulianna C. Taritsa, Eric T. Fossel · 2025 · Frontiers in Pharmacology
Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine
Andrea Orué, Valery A. Chavez, Mary Strasberg–Rieber, Manuel Rieber · 2016 · BMC Cancer
Quantifying Cellular Repair, Misrepair and Apoptosis Induced by Boron Ions, Gamma Rays and PRIMA-1 Using the RHR Formulation
Anders Brahme · 2022 · Radiation Research
Thioredoxin and glutathione reductases
Elias S.J. Arnér · 2022 · Elsevier eBooks
Evaluating targeted therapies in older patients with TP53 -mutated AML
Jean M.G. Sabile, Ronan T. Swords, Jeffrey W Tyner · 2024 · Leukemia & lymphoma/Leukemia and lymphoma
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility
Pooja Anil Shah, Klas G. Wiman, Karen M. Cichowski, Jordi Ahnert Rodon · 2025 · American Society of Clinical Oncology Educational Book
Targeting the p53/xCT/GSH Axis with PRIMA-1Met Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia
Martina Pasino, Andrea Speciale, Silvia Ravera, Giovanna Cutrona, Rosanna Massara, Nadia Bertola, Maurizio Viale, Irena Velkova, Andrea Nicola Mazzarello, Franco Fais et al. · 2025 · International Journal of Molecular Sciences
Refractory alveolar rhabdomyosarcoma in an 11-year-old male
Cora A. Ricker, Andrew D. Woods, William Simonson, Melvin Lathara, Ganapati Srinivasa, Erin R. Rudzinski, Atiya Mansoor, Robert G. Irwin, Charles Keller, Noah Berlow · 2021 · Molecular Case Studies
PK11007 Covalently Inhibits Thioredoxin Reductase 1 to Induce Oxidative Stress and Autophagy Impairment in NSCLC Cells
Hanziyi Zhou, Shibo Sun, Haowen Liu, Tong Li, Yiran Xu, Rui Ryan Yang, Haiyan Liu, Leiyu He, Weiping Xu, Shui Guan et al. · 2025 · Antioxidants
Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia
Philipp Makowka, Verena Stolp, Karoline Stoschek, Hubert L. Serve · 2021 · Biological Chemistry
Pro-senescence Therapy for Cancer: Time for the Clinic
Madhuri Kalathur, Diletta Di Mitri, Andrea Alimonti · 2014 · Springer eBooks
Peripheral T-cell lymphoma diagnosis: building a molecular tool
Miguel Angel Piris · 2020 · Haematologica
Regulation and therapy: the role of ferroptosis in DLBCL
Yifan Wang, Zhengmei He, Xinyu Dong, Yiming Yao, Qiuni Chen, Yuye Shi, Yuan Deng, Quane Zhang, Liang Yu, Hong Wang · 2025 · Frontiers in Pharmacology
Eprenetapopt in combination with Palbociclib exerts synthetic lethality in mantle cell lymphoma
Ling Dong, Yue Zhang, Fei Chen, Wenxing Jiang, Siyu Qian, Wenting Song, Shengnan Yang, Xiaolong Wu, Zhaoming Li, Mingzhi Zhang · 2026 · Translational Oncology
Wild-Type p53 Protein Enhances APR-246-Induced Cytotoxicity in Acute Myeloid Leukemia and Normal Hematopoietic Stem/Progenitor Cells
John Bradley Cart, David Zhu, Lucas Norris, Sadhna O. Piryani, Li-Chan Chang, Christine Elissa Eyler, Chang‐Lung Lee · 2026 · International Journal of Molecular Sciences
Research Progress of Mutant p53 as a Potential Therapeutic Target for Breast Cancer
俊臻周 · 2021 · Advances in Clinical Medicine
Research Progress of p53 Gene and Tumor
祥朱 · 2022 · World Journal of Cancer Research
Research Progress of Multidrug Resistance Mechanism and Reverser in Tumor
牡丹郭 · 2020 · Journal of Organic Chemistry Research
Activation of TAp73 and inhibition of thioredoxin reductase for improved cancer therapy in TP 53 mutant pancreatic tumors
Pilar Acedo, Aristi Potamitou Fernandes, Joanna Zawacka‐Pankau · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
Covalent Modification of p53 by (E)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
Katie M. Brown, Marco Robello, Andrew J. Perciaccante, Jerry C. Dinan, Tapan Kumar Maity, Gaelyn C. Lyons, Jay Prakash Kumar, Stewart R. Durell, Harichandra D. Tagad, Daniel Schilling et al. · 2024 · ACS Pharmacology & Translational Science
APR-246 & COTI-2 increase chemoradiotherapy sensitivity via ROS-induced DNA damage and ferroptosis in p53 mutant HPV negative head and neck squamous cell carcinoma
Tycho de Bakker, Morgane M. Cogels, Chrysanthi Iliadi, Sébastien Penninckx, Philippe Martinive, Dirk Van Gestel · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
Establishment and characterization of a new immortalized human oral keratinocyte (HOK) cell line harboring various TP53 mutations
Mei Zhao, Zhiyi Liu, Mutsuki Kawabe, Abdullah A. Osman, Mitchell J. Frederick, Jeffrey N. Myers · 2025 · Oral Oncology
TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches
Shweta Deshpande, Wing Fai Li, Junmin Song, Mark Forsberg, Claudio Cerchione, Giovanni Martinelli, Marina Y Konopleva · 2026 · Frontiers in Oncology
Identification par séquençage de l'exome de la dérégulation des voies de signalisation dans le myélome multiple et leurs conséquences fonctionnelles, notamment sur la voie p53
Benoît Tessoulin · 2018 · theses.fr (ABES)
Etude de la ferroptose dans les leucémies aiguës myéloïdes : nouvelles stratégies thérapeutiques
Rudy Birsen · 2020
The p53/Mdm2 Pathway in Hepatocellular Carcinoma: From Molecular Pathogenesis to Targeted Therapies
Keara Kirkness, Derek A. Mann · 2026 · Livers
Mammalian Thioredoxin Reductases: Opposing or Facilitating Cellular NADPH Oxidase Activities?
Radosveta Gencheva, Lucia Coppo, Elias S.J. Arnér · 2026 · Springer eBooks
Structural Optimization Strategy for α,β ‐Unsaturated Ketone TrxR Inhibitors: From Enhanced Pharmacokinetics to Improved Tumor Selectivity
Xinyan Wang, Yanqing Du, Wei Ning, Baojun Shen, Guodong Liang, Yan Zhao, Lu Ga · 2026 · Archiv der Pharmazie
BindingDB Entry 50021131: An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
BindingDB · 2025 · UC San Diego